Kelun-Biotech presents groundbreaking results at ASCO Annual Meeting

In Chengdu, China, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is set to present findings from six significant clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place from May 30 to June 3, 2025, in Chicago, Illinois. Among the data showcased are results related to their groundbreaking TROP2 antibody-drug conjugate (ADC) sac-TMT, as well as the anti-PD-L1 monoclonal antibody tagitanlimab and the RET inhibitor KL590586. These studies mark pivotal advancements in cancer treatment, particularly highlighting the recent approval of sac-TMT for use in EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in China. The approval of sac-TMT represents a significant milestone, being the first such therapy approved globally for lung cancer. The approval process for sac-TMT was supported by compelling results from various studies presented at the conference. In the first study, patients with advanced non-squamous NSCLC receiving sac-TMT in combination with tagitanlimab exhibited a confirmed overall response rate (ORR) of 59.3% and a median progression-free survival (PFS) of 15 months. Further subgroup analysis indicated even better outcomes for patients with a PD-L1 tumor proportion score greater than or equal to 50%. In a second study focusing on patients with previously treated locally advanced or metastatic NSCLC with uncommon EGFR mutations, preliminary results suggest a modest but promising response. An enrollment of 42 patients revealed an ORR of 35.7%, with a median PFS of 9.5 months. The safety profile remained favorable, with no treatment-related adverse events leading to discontinuation or mortality among participants. These findings reinforce the potential of sac-TMT as a viable treatment option, complementing existing therapies and addressing unmet medical needs in specific patient populations. Kelun-Biotech continues to innovate in the oncology space, having licensed exclusive rights to MSD (Merck & Co.) for the development and commercialization of sac-TMT outside Greater China. Alongside collaborative efforts with MSD, which is conducting global clinical trials combining sac-TMT with pembrolizumab, the company remains committed to advancing cancer treatment options and improving patient outcomes. As these studies unfold, the results shared at the ASCO Annual Meeting are expected to ignite further discussions on effective therapies for various cancer types, establishing Kelun-Biotech as a key player in the biopharmaceutical landscape.